Medipacs Gel Pumps First Fluids .
News Release
August 24 , 2006
Medipacs, a Tucson biotech company, has announced the successful operation and pumping of the first fluids through the Medipacs polymer gel proof of concept device. The proprietary Digital PumpT technology is being developed to drive or pump fluids for drug delivery and infusion therapies in the medical market.
This first pump10 cell prototype is the precursor to medical applications of the new technology that Medipacs is currently developing. Able to operate on under 3 volts of power the new device has produced repeated results by pumping, very small, milligram amounts of water continuously over several hours and has attained pressures of over 3 psi. The pump has no mechanical parts and works by using polymer gels that expand and contract from the electrical current. The new device is controlled by a small computer chip that is programmed to pump the desired rates.
Plans for the new Digital PumpT technology include a new medical infusion pump, around the size of a cell phone, that will provide a low cost alternative to expensive infusion pumps currently on the market. Eventually the pumps will be available in other devices such as a drug delivery patch and implantable devices that can monitor patient fluids and deliver medicine at the same time.
"This is a major milestone the company has achieved as we continue down our development path and the Medipacs pump was partially funded by a SBIR Grant from the Office of the Secretary of Defense and the US Army Medical Research Command. " says company representative Laurie Hassey.
The Medipacs device is not FDA approved and is in research and development stages.
Contact Information:
Laurie Hassey 520-382-3264
VP Marketing
lhassey@medipacs.com
www.medipacs.com
This news release may contain forward looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors, both known & unknown, could influence actual results may be substantial & include those described in documents filed with regulatory authorities. No assurances can be given that any of the events anticipated by the forward looking statements will transpire or occur, or if any of them do so, what benefits the company will derive there from.
|
